The Supply Lines: Which Companies are Making the News?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms). Which companies are making the news?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging. Which companies are making the news?

Companies making news at DCAT Week 2023 
The Drug, Chemical & Associated Technologies Association (DCAT) held its flagship event, DCAT Week, from March 19 to March 23, 2023, where bio/pharma companies and suppliers convened in New York for high-level business meetings, education programs featuring thought leaders, and networking events. With executives from the bio/pharma industry assembled, DCAT Member Companies took the opportunity to highlight recent news from across the bio/pharmaceutical manufacturing value chain.  

In the March 31, 2023, issue of DCAT Value Chain Insights, we featured companies taking to the podium at the DCAT Member Company Announcement Forum, where senior executives highlighted major news from their companies. Participating in the Forum were: Samsung Biologics, WuXi STA, Bachem, Siegfried, WuXi Biologics, Lonza, Catalent, Thermo Fisher Scientific, Flamma, Porton Pharma, BSP Pharmaceuticals, Granules, Meridian Medical Technologies/Kindeva Drug Delivery, and Incog BioPharma Services. See story, Executives Highlight Expansion Plans at the DCAT Member Company Announcement Forum for a roundup of their news announcements.  

In this issue, DCAT Value Chain Insights highlights other companies making the news in chemical/chemical API manufacturing, biologics manufacturing, formulation development and drug-product manufacturing, end-to-end manufacturing (both drug substances and drug products), and packaging. 

See related stories and the companies making the news below: 

From DCAT Week 2023: Supplier News: Chemicals/Chemical API Manufacturing featuring news from PharmaBlock, Seqens, Polpharma API, Cambrex, Actylis, Avantor, Univar, Procos, Maithri Drugs, Dr. Reddy’s Laboratories, Jubilant Biosys, C2 Pharma, and ChemCon. 

From DCAT Week 2023: Supplier News: Biologics Manufacturing featuring news from BioVectra, Scorpius BioManufacturing, Avid Bioservices, IDT Biologika, Landmark Bio, and Mabion. 

From DCAT Week 2023: Supplier News: Formulation Development/Drug Product Manufacturing featuring news from Evonik, Carbogen Amcis, Vetter, Nanoform, Mikart, Ascendia Pharmaceuticals, Bushu Pharma, and Lifecore Biomedical. 

From DCAT Week 2023: Supplier News: End-to-End (Drug Substance and Drug Product) Mfg with news from CordenPharma and BioDuro Sundia 

From DCAT Week 2023: Supplier News: Packaging featuring news from PCI Pharma Services, Bormioli, and Tedor Pharma Services. 

Recent Feature Articles

Bio/Pharma’s Top 10: Biologic-Based Drugs

By
How do biologic-based drugs rank among leading products of the top bio/pharma companies? Which companies and products are leading the pack? DCAT Value Chain Insights takes an inside look.

Cancer Drugs: Market Outlook & Product Innovation

By
Global spending on oncology drugs, the industry’s largest therapeutic sector, is projected to reach $409 billion by 2028. What product innovation, trends, and commercialization strategies are at play?

Supplier Risk Management: The Double-Edged Sword

By
Mitigating supplier risk is imperative, but how can that goal be balanced with the challenges of supplier consolidation,  industry capacity limitations, internal constraints, and other uncertainty to assure supply? An upcoming DCAT webinar will provide a “buy-and-sell side” view on best practices and new insights on how to better assess and mitigate risk in sourcing and supplier selection and the initial make-versus-buy decision.

Manufacturing and Supply Lines: Cell & Gene Therapies

By
Although a niche market, cell and gene therapy development and manufacturing is an active area of investment by select bio/pharmaceutical majors, CDMOs/CMOs and smaller bio/pharmaceuticals. Which companies are expanding? DCAT Value Chain Insights rounds up the latest developments.